I bring healthcare to people's homes in Singapore. AI is changing home care, but it can't replace clinicians.
Homes will become the new center of care, with AI enabling this shift, said Dr. Shravan Verma.
AI will not replace clinicians, especially in home settings, the cofounder and CEO of Speedoc said.
AI can't replicate doctors' presence, empathy, and nuanced judgment in uncertain or complex conditions.
This as-told-to essay is based on a conversation with Dr. Shravan Verma, the cofounder and CEO of Speedoc, a Singapore-based health tech startup. This interview has been edited for length and clarity.
As someone who has worked in both tertiary hospitals as well as some underserved environments, I saw the opportunity to create a virtual hospital that brings healthcare directly to where patients are, starting with their homes.
Why should access to hospital-grade care be dependent on geography or infrastructure? The home will become the new center of care, and AI will be the invisible infrastructure enabling this shift.
With AI software becoming more sophisticated and AI-enabled hardware becoming more accessible, care will become more personalized.
I see the future of home care as a hybrid, with AI-enabled self-care tools integrated into regulated, human-involved systems.
Singapore and the region are more ready than we think. In Singapore, we're already seeing strong policy alignment and public trust in digital systems. Even the patient mindset is maturing around receiving care outside traditional hospitals.
AI is already a foundational layer of our operations. Our command center uses AI to triage patient cases, optimize our logistics for clinician dispatch, and even anticipate escalation risks.
For example, AI models continuously analyze data from devices like pulse oximeters, BP monitors, or even passive sensors. If a patient's vitals begin trending dangerously, clinicians are alerted before deterioration sets in. We've prevented emergency room visits this way.
The next phase is using AI for predictive care, orchestration, preempting deterioration in chronic patients, automating routine follow-ups, and eventually building an AI copilot for our clinicians.
Clinicians expect systems to support and not slow down their work.
Our nurses and doctors are asking for tools that reduce admin burden, triage smarter, and give them more actionable insights.
Patients, too, are increasingly comfortable with these digital touchpoints, but they do want these to feel personalized and intelligent.
AI will transform but not replace the clinician role, especially in home settings.
Their role becomes more relational as AI simplifies documentation and supports better decision-making.
AI can't replicate the presence, empathy, and nuanced judgment in uncertain or complex conditions. It can't speak with family and understand what's best for the patient.
AI can tell you — worst case — you're having a heart attack, but then what do you do about it?
I know the diagnosis of a heart attack, but I need to be sent immediately to a hospital, make sure that I get stented, and get the catheterization, which is still very human-driven.
Somebody also has to ensure continuity, ensure the administration of treatments and follow-ups, and ensure that the patients are improving as they're supposed to. Many of the conditions we treat at home also require IV drips, IV antibiotics, blood tests, and urine tests.
Chatbots and AI tools can handle the first mile of care, but they must escalate to qualified professionals when needed.
We need to be vigilant about bias in training data and sometimes a lack of contextual nuances in understanding what a patient's condition is.
One of the key challenges with AI is confabulation, which is AI coming up with analysis or data that didn't exist for the patient. Governance, transparency, and auditability must be baked into every AI deployment.
When it comes to AI-driven home care, the key is not to lead with AI but with outcomes and convenience. Patients don't really ask, "Is this AI?" They ask, "Is this faster, safer, more personalized?"
When AI helps a patient get triaged within minutes or enables a nurse to show up at the right time with the right medication, that builds confidence.
The real unlock is making sure AI remains transparent, empathetic, and always augments, not replaces, the human touch.
Do you have a story to share about AI in healthcare? Contact this reporter at cmlee@insider.com.
Read the original article on Business Insider
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Indonesia Telecoms Industry Report: 2025-2032: Broadband Expansion, Spectrum Intelligence, and Tower Trends
This comprehensive report offers in-depth analysis, forecasts, and insights into mobile market transformations, key for strategic planning and investment. Dublin, June 16, 2025 (GLOBE NEWSWIRE) -- The "Indonesia Telecoms Industry Report: 2025-2032" report has been added to offering. The Indonesia Telecommunications Industry Report, 2025-2032 includes an overview of the Indonesian market dynamics, market sizing, market forecasts, analysis, insights and key trends. The report provides the most comprehensive and up-to-date analysis of Southeast Asia's largest digital economy and its fast-evolving telecoms market. Spanning mobile, fixed broadband, satellite, tower, and submarine infrastructure, the report offers deep insights, reliable datasets, and strategic intelligence for investors, operators, regulators, and digital ecosystem players. Why You Should Buy This Indonesia Telecoms Industry Report: Benefit from the latest market opportunities Understand the threats to your operations and investments and protect your company against future risks Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market Get a full view of the competitive landscape to assess your market position. Forecasts as a key input for successful budgeting and strategic business planning in the telecoms market Target business opportunities and risks in the telecoms sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments Assess the activities, strategy and market position of your competitors, partners and clients via our Operators Profiles Indonesia Telecoms Industry Report: Key Developments, Growth Prospects, and Investment Opportunities Key Themes CoveredMobile Market Transformation In-depth analysis of the XL Axiata-Smartfren merger, marking the transition to a three-operator market alongside Telkomsel and Indosat Ooredoo Hutchison. Subscriber and revenue forecasts to 2032, with ARPU trends, service revenue mix, and spectrum holdings by operator. Competitive positioning, operator KPIs, and market share evolution across mobile, broadband, and tower markets. Fixed & Satellite Broadband Broadband subscribers forecast to reach 29 million by 2032, with household penetration rising to 35%. Profiles of key players: Telkom Indonesia, XL Home/Link Net, MyRepublic, Icon+, Moratelindo, and Starlink. Satellite broadband users set to exceed 3 million by 2032, fuelled by new entrants and LEO constellations. Spectrum & Infrastructure Intelligence Comprehensive spectrum allocation benchmarking across 850-2300 MHz bands and subscriptions per MHz by country. Indonesia's spectrum scarcity compared regionally with high subscribers-per-MHz ratio, pressuring network quality and investment cycles. Tower Market Landscape Detailed tower and tenancy data covering 126,000 towers, with operator KPIs for Mitratel, Tower Bersama, Protelindo, Centratama/Edgepoint, and more. Insights on tower consolidation trends, tenancy ratios, average revenue per tower, and site decommissioning risks post-operator M&A. International Infrastructure & Cross-Border Connectivity Full submarine cable map and database of over 20 active and planned systems, including SEA-ME-WE, Bifrost, Apricot, Echo, and SJC. Review of IXP throughput, international bandwidth, and internet backbone capacity benchmarks across 39 European and Asia-Pacific markets. 5G, NTN, & Satellite Disruption Strategic profiles of Starlink, AST SpaceMobile, Lynk, Kuiper, and others entering the NTN/5G direct-to-device space. Indonesia's role in global LEO infrastructure as satellite broadband supplements rural 5G and fiber gaps. M&A and Diversification Outlook Evaluation of telco-driven diversification into fintech, logistics, e-commerce, and data centre infrastructure. Strategic investments from Telkomsel in GoTo (Tokopedia + Gojek), and LinkAja's role in digital financial services. Why This Report? Indonesia is undergoing a once-in-a-decade telecom reset, with consolidation, 5G rollout delays, spectrum constraints, and pressure on ARPU defining the industry. This report offers: Independent, data-backed insights trusted by investors and regulators Coverage of all major players and infrastructure segments Tailored insights for strategic planning, market entry, and due diligence Key Topics Covered: 1 Key Statistics1.1 Indonesia's Population1.2 Indonesia's Economy1.3 Indonesia's GDP 2 Overall Telecommunications Market, 2018-20322.1 Market Overview2.2 Historical Telecommunications Market Revenue, 2018-20322.3 Overall Telecommunications Market Forecast, 2024-20322.4 Telecommunications Market Capital Expenditure, 2018-20322.4.1 Historical Telecommunications Capex Spend, 2018-20242.4.2 Capex to Revenue Benchmark2.4.3 Capex to GDP Benchmark2.4.4 Telecommunications Capex Spend Forecast, 2024-2032 3 Telecommunications Operators Profile3.1 Telkom Indonesia Profile3.1.1 Telkom Revenue and EBITDA Mix3.1.2 Telkomsel3.2 Indosat Ooredoo Hutchison Profile3.2.1 IOH Revenue and EBITDA Mix3.2.2 Tri Indonesia (Historical Only)3.2.3 Tri Indonesia Revenue and EBITDA Mix3.3 XL Axiata3.3.1 XL Axiata Revenue and EBITDA Mix3.3.2 Link Net3.3.3 Link Net Revenue, EBITDA and Capex Mix3.4 Smartfren Profile3.4.1 Smartfren Revenue, EBITDA and Capex Mix3.5 Other Players Profile3.5.1 MNC Vision3.5.2 BizNet3.5.1 Icon+ 4 Mobile Market4.1 Mobile Subscribers Historical and Forecast, 2018-20324.1.1 Mobile Subscribers Historical, 2018-20244.1.2 Mobile Subscribers Market Share, 2018-20244.1.3 Indonesia Smartphone Share, 20254.1.4 Mobile Subscribers Forecast, 2024-20324.1.5 Indonesia Mobile Subscribers by Generation (2G, 3G, 4G & 5G) Forecast, 2024-20324.2 Mobile Revenue Historical and Forecast, 2018-20324.2.1 Historical Mobile Revenue, 2018-20244.2.2 Mobile Revenue Market Share, 2018-20244.2.3 Mobile Revenue Forecast, 2024-20324.2.4 Mobile Subscribers ARPU, 2018-20244.3 Spectrum Holdings4.3.1 5G Development and Launches4.3.2 Mobile Frequencies Portfolios Analysis4.3.3 Spectrum Depth Benchmark by Country4.4 Asia Pacific Mobile Download Data and Pricing Benchmark - 20254.5 Mobile Speed Tests4.5.1 Ookla Mobile Speed Tests4.5.2 OpenSignal 5 Broadband Market5.1 Fixed Broadband Subscribers Historical, 2018-20245.2 Fixed Broadband Subscribers Forecast, 2024-2032 6 Satellite Internet Connectivity6.1 Comparing LEO, MEO, and GEO Satellite Orbits6.1.1 LEO and GEO Satellite Comparison6.2 Satellite Broadband Providers Operators, 20256.3 5G NTN: The Next Generation of Satellite Connectivity6.3.1 5G NTN Overview6.3.2 The Rationale Behind 5G NTN6.3.3 Technical Aspects of 5G NTN6.3.4 Potential Applications for 5G NTN6.3.5 Challenges in Implementation6.3.6 5G NTN Satellite Providers6.4 Satellite Internet Market Analysis, 2024-20326.4.1 Market Landscape of Satellite Broadband Subscribers, 20256.5 Indonesia Satellite Broadband Subscribers Forecast, 2024-2032 7 Fixed Telecommunications Infrastructure Investments7.1 Fixed Digital Infrastructure7.1.1 Palapa Ring Completed7.1.2 FTTH - 20m premises to go7.1.3 Submarine Cables 8 Indonesia Telecom Towers Infrastructure Landscape8.1 Indonesia Telecom Towers Market Analysis, 20258.1.1 Indonesia Telecom Towers Market Overview8.1.2 Indonesia Telecom Towers Background8.2 Indonesia Tower Market Competitive Landscape Comparison8.3 Indonesia Telecom Towers & Rooftops Market Forecast8.3.1 Indonesia Telecom Towers and Rooftops, Revenue, Penetration Forecast, 2024-20328.4 Mitratel Profile8.4.1 Mitratel Revenue, EBITDA and Towers, 2018 - 20248.5 Tower bersama Profile8.5.1 Tower Bersama Revenue, EBITDA and Towers, 2018 - 20248.6 Protelindo Profile8.6.1 Protelindo Revenue, EBITDA and Towers, 2018 - 20248.7 Centratama Menara Profile8.7.1 Centratama Menara Revenue, EBITDA and Tower Statistics, 2018 - 20248.8 Tower Density Benchmark 9 Thematics/Opportunities9.1 Consolidation Opportunities9.2 Diversification Opportunities9.3 6G on the Horizon 10 Telco Transaction Database For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio


Medscape
15 minutes ago
- Medscape
HL: Second-Line Sintilimab Plus Chemo Bests Chemo Alone
The programmed cell death protein 1 (PD-1) inhibitor drug sintilimab in combination with the standard chemotherapy regimen of ifosfamide, carboplatin, and etoposide (ICE) shows significant benefit as a second-line treatment for classical Hodgkin lymphoma (HL) vs ICE chemotherapy alone, with relatively high rates of complete responses and favorable progression-free survival (PFS). The results are from the phase 3 ORIENT-21 trial, conducted in China, which is believed to represent the first randomized study of a PD-1 inhibitor plus chemotherapy compared with chemotherapy alone in the challenging second-line setting of classical HL. METHODOLOGY: The study included 81 patients with classical HL who failed first-line standard chemotherapy, with a median age of 33, including 12.3% over the age of 50. Of the patients, 23.5% had stage III disease, and 35.8% had stage IV disease; 56.8% were relapsed, and 43.2% were refractory. After a safety run-in phase, patients were randomized 1:1 to treatment either with sintilimab or placebo plus ICE for six cycles. Those with disease progression continued either on sintilimab or placebo monotherapy. TAKEAWAY: With a median follow-up of 38.4 months in the modified intention-to-treat (mITT) population (n = 71), sintilimab plus ICE showed a significantly higher complete response (CR) rate of 61.8% compared with 32.4% with ICE alone ( P = .0295). = .0295). Consistent results were observed in the ITT population of 81 patients, with a CRR of 61.4% vs 32.4% ( P = .0105). = .0105). The median duration of complete response was not reached in the sintilimab plus ICE arm, while it was 20.7 months in the placebo plus ICE group. The median PFS in the ITT population was not reached with sintilimab plus ICE vs 9.0 months with placebo and ICE (HR, 0.48), with more favorable PFS among CR patients vs non-CR patients in each treatment arm. Treatment-emergent adverse events (TEAEs) were similar in both arms (18.6% and 13.5%, sintilimab plus ICE and ICE alone, respectively), with no TEAEs resulting in death. IN PRACTICE: 'As the second-line treatment for classical Hodgkin lymphoma, sintilimab plus ICE significantly improved complete response rates and showed a trend of improved PFS compared with placebo plus ICE,' said first author Peng Liu, of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. The results 'may provide data for a stem-cell transplant-free approach for some patients in second-line classical Hodgkin lymphoma,' commented Sarah C. Rutherford, MD, associate professor of clinical medicine at Weill Cornell Medicine in New York City, a discussant for the study at the meeting. SOURCE: The study, abstract #7007, was presented at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago. LIMITATIONS: Longer follow-up is needed, 'especially to understand the impact of no autologous stem cell transplantation,' Rutherford noted. Results from a larger sample size are warranted, the authors added. As the study was conducted in China, generalizability of the results to other populations should be considered. DISCLOSURES: The study was funded by Innovent Biologics (Suzhou) Co., Ltd., in China. Rutherford's disclosures include relationships with Abbvie, ADC Therapeutics, Bristol Myers Squibb, Genmab, Incyte, Karyopharm Therapeutics, Kite Pharma, Pfizer, and Seagen.


CNN
15 minutes ago
- CNN
Taiwan puts companies behind China's AI ambitions on export control list
Taiwan has added China's tech titan Huawei and chip giant Semiconductor Manufacturing International Corporation (SMIC) to its export control list, stepping up efforts to align with Washington's crackdown on companies driving Beijing's artificial intelligence ambitions. Citing 'concerns over weapons proliferation and national security,' Taiwan's International Trade Administration updated its list of what it calls strategic high-tech commodities entities last week to include Huawei and SMIC, among hundreds of other entities in China, Myanmar, Russia, Iran and Pakistan. Under the restrictions, Taiwanese businesses will be required to apply for permits before exporting to the listed firms. The new rules were announced amid escalating US-China tensions over advanced technologies including semiconductors and AI. Washington has grown increasingly concerned about its tech being used in Chinese military applications. Just last month, the Trump administration restricted sales of chip design software to China in its ongoing trade war with Beijing. The latest move by Taiwan underscores its government's active approach in working with the US – its largest unofficial partner – to plug any loopholes in tech restrictions against Beijing. China claims self-governing Taiwan as part of its territory despite having never controlled it. Taiwan Semiconductor Manufacturing Company (TSMC), the world's largest contract chipmaker, which supplies Apple and AI giant Nvidia, had produced microchips for Huawei until 2020, when the first Trump administration effectively banned it from supplying the Chinese company. Since the ban, Huawei has turned to SMIC – which has also faced US restrictions – to source chips. With US restrictions already in place, experts said Taiwan's move to tighten the screws on Huawei, SMIC and their subsidiaries is largely symbolic. CNN has reached out to Huawei and SMIC for comment. 'This reflects the Taiwanese government's clearer intent to align its export control regulations more closely with those of the United States,' said Min-yen Chiang, a nonresident fellow at the Research Institute for Democracy, Society, and Emerging Technology, a government-funded think tank in Taipei. 'In fact, Taiwan is the second country in the world – after the US – to publicly place SMIC and Huawei on an export control list.' Taiwan's 'proactive' step signals that the government recognizes the need to play an active role in cooperating with the American government and addressing the security concerns at stake, Chiang said. 'From what I understand, the US government has long hoped that Taiwan would take greater initiative in regulating sensitive exports on its own, rather than simply following Washington's lead,' he added. Late last year, TSMC-made chips were reportedly found in a Huawei AI processor. While TSMC clarified it had not been supplying Huawei since 2020, the report stoked concerns in Washington that chips made by the Taiwanese company and intended for another Chinese firm, Sophgo, might have been rerouted to Huawei. Reuters has reported that the US Department of Commerce has been investigating the incident and that TSMC could face a penalty of $1 billion or more from Washington. In November, the department also ordered the Taiwanese company to halt shipments of advanced chips to China. 'While the new controls aren't a direct response to that specific incident, the discovery of TSMC-made chips in Huawei products last year served as a wake-up call: It prompted both TSMC and the Taiwan government to re-examine existing oversight mechanisms and identify gaps in preventing indirect supply chain loopholes,' said Brady Wang, associate director at Counterpoint Research, a market analysis firm. During his first term, US President Donald Trump imposed targeted restrictions on companies like Huawei, banning American firms from partnering with them and restricting the sale of chips to them. In 2022, then-President Joe Biden intensified these efforts, curbing the sale of advanced semiconductors to China over concerns they could power its military. The controls were subsequently expanded to include restrictions on sales of chipmaking equipment, high-bandwidth memory chips and even products manufactured outside the United States using American technology. The mounting restrictions have put heavy pressure on China's strategic sectors that Chinese leader Xi Jinping has prioritized, including semiconductors and AI. But Huawei and SMIC have made some strides in the production of advanced chips, and Beijing has pinned its hopes on these companies to lead innovation. Although the US restrictions initially crippled its business, Huawei made a remarkable comeback in 2023 with the introduction of its Mate 60 smartphone, powered by advanced chips made by SMIC. The launch of the handset even triggered investigations by the US government. Galen Zeng, a senior research manager at IDC, a market intelligence firm, said Monday that the timing of Taiwan's export controls reflects multiple strategic considerations, including Washington's concerns about the advanced chips found in Huawei's devices. 'Coupled with US concerns over indirect supply routes, these developments have pushed Taiwan to tighten its export control mechanisms to enhance supply chain transparency,' he said. While Huawei and SMIC may need to seek domestic alternatives in response to the export controls, restrictions like these would ultimately benefit Chinese suppliers, Zeng said. 'In the long term, this is likely to accelerate China's push for semiconductor self-sufficiency, benefiting domestic equipment, materials, and component suppliers,' he said. In a rare interview last week, Ren Zhenfei, the founder of Huawei, downplayed the impact of the US technology restrictions on Huawei and China overall, while saying its chip technology remains one generation behind US technology. 'There's actually no need to worry about the chip issue. By using methods like stacking and clustering, the computational results are comparable to the most advanced levels,' he said, referring to the industry approach of bundling multiple chips to achieve higher performance.